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 Tacrolimus is an immunosuppressive drug mainly through down-regulation of T cell activation. Topical 
application of tacrolimus is therapeutically effective on chronic inflammatory skin diseases. However, there has 
been a concern about increased risk of UV exposure-induced skin cancer facilitated by topical tacrolimus, 
because of its potential suppression of anti-tumor immunity. The aim of this study was to examine whether 
topical tacrolimus treatment facilitated UV-induced carcinogenesis using K5.Stat3C mice. K5.Stat3C mice 
expressed constitutively activated Stat3 in epidermis and therefore were prone to skin cancers, induced by the 
carcinogenesis regimen of UVB irradiation. To verify immunosuppressive potential of tacrolimus, an experiment 
of contact hypersensitivy (CH) by dinitrofluorobenzene (DNFB) was conducted. Four days after sensitization of 
DNFB in the back skins of K5.Stat3C mice, DNFB was challenged onto the ear skins twice weekly, with or 
without topical tacrolimus treatment. Tacrolimus significantly attenuated ear swelling and dermatitis induced by 
repeated application of DNFB, indicating that tacrolimus ameliorated the CH response as expected. Finally, 
K5.Stat3C mice were subjected to the UVB carcinogenesis regimen which induced epidermal atypia after 12 
weeks and squamous cell carcinoma after 16 weeks. Immediately after every irradiation, we topically treated 
them with tacrolimus or vehicle onto the right ears and left ears, respectively. Histological examination revealed 
that there was no difference between the two groups in the latent period of onset of epidermal atypia, cancer 
development or histological appearance. Taken collectively, topical tacrolimus did not facilitate UVB-induced 
carcinogenesis, although it suppressed the CH response to hapten. 
